Vertex Slumps Premarket On Halting Liver-Disease Drug Development By

By Dhirendra Tripathi – Vertex Pharmaceuticals (NASDAQ:) stock plunged 12% in Friday’s premarket trading after the company decided not to go ahead with its attempt to develop a drug for a rare liver disorder.

The is a setback to the biotech’s attempt to broaden its offerings beyond cystic fibrosis drugs.

After reporting results from a mid-stage trial, Vertex said the treatment, VX-864, isn’t likely to substantially benefit patients. This is the second time the company has called off development of a similar compound due to safety issues.

The two attempts were aimed at developing a treatment for alpha-1 antitrypsin deficiency. It’s an inherited disease where the patient’s liver doesn’t make a protein needed to protect itself and the lungs.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

See also  Asda loses equal pay claim, as garden furniture boom boosts UK retail sales – business live | Business


Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.